Gland Pharma (NSE:GLAND) Institutional Ownership: 32.48% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAND Gland Pharma Ltd NSE:GLAND
84 GF Score
Price ₹2,465.10
GF Value ₹2,140.91
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Gland Pharma Institutional Ownership?

Gland Pharma NSE:GLAND -0.93% 84 Institutional Ownership is 32.48% as of Jul. 16, 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,140.91 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Gland Pharma's institutional ownership is 32.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Gland Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Gland Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

Gland Pharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Institutional Ownership Chart

Gland Pharma Historical Data

The historical data trend for Gland Pharma can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 34.67 34.81 35.63 35.94 36.19 36.23 36.28 36.16 34.56 32.48
NSE:GLAND
84GF Score
Gland Pharma Ltd NSE:GLAND
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 32.48% mean?
Gland Pharma (NSE:GLAND) has a Institutional Ownership of 32.48% as of Jul. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Institutional Ownership too high?
Gland Pharma's current Institutional Ownership is 32.48%. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Institutional Ownership compare to ZTS and UTHR?
Gland Pharma's Institutional Ownership of 32.48% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Gland Pharma and its competitors. Gland Pharma's current Institutional Ownership is 32.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,140.91, compared to a current price of ₹2,465.10 — trading 15.1% above its estimated fair value. The current Institutional Ownership is 32.48%. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Institutional Ownership is 32.48% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,465.10 is trading 15.1% above its estimated GF Value™ of ₹2,140.91. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Institutional Ownership: 32.48%
  • GF Value™: ₹2,140.91 vs. price of ₹2,465.10 (15.1% above fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score

Get the complete analysis for NSE:GLAND

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,465.10
Price
₹2,140.91
GF Value